BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18580968)

  • 1. Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells.
    Yokoyama T; Iwado E; Kondo Y; Aoki H; Hayashi Y; Georgescu MM; Sawaya R; Hess KR; Mills GB; Kawamura H; Hashimoto Y; Urata Y; Fujiwara T; Kondo S
    Gene Ther; 2008 Sep; 15(17):1233-9. PubMed ID: 18580968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
    Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.
    Oh E; Hong J; Kwon OJ; Yun CO
    Sci Rep; 2018 Jan; 8(1):1420. PubMed ID: 29362367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.
    Hasei J; Sasaki T; Tazawa H; Osaki S; Yamakawa Y; Kunisada T; Yoshida A; Hashimoto Y; Onishi T; Uno F; Kagawa S; Urata Y; Ozaki T; Fujiwara T
    Mol Cancer Ther; 2013 Mar; 12(3):314-25. PubMed ID: 23315976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic adenoviruses for the treatment of brain tumors.
    Gomez-Manzano C; Fueyo J
    Curr Opin Mol Ther; 2010 Oct; 12(5):530-7. PubMed ID: 20886384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
    Liikanen I; Ahtiainen L; Hirvinen ML; Bramante S; Cerullo V; Nokisalmi P; Hemminki O; Diaconu I; Pesonen S; Koski A; Kangasniemi L; Pesonen SK; Oksanen M; Laasonen L; Partanen K; Joensuu T; Zhao F; Kanerva A; Hemminki A
    Mol Ther; 2013 Jun; 21(6):1212-23. PubMed ID: 23546299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo.
    Gomez-Gutierrez JG; Nitz J; Sharma R; Wechman SL; Riedinger E; Martinez-Jaramillo E; Sam Zhou H; McMasters KM
    Virology; 2016 Jan; 487():249-59. PubMed ID: 26561948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy.
    Ulasov IV; Shah N; Kaverina NV; Lee H; Lin B; Lieber A; Kadagidze ZG; Yoon JG; Schroeder B; Hothi P; Ghosh D; Baryshnikov AY; Cobbs CS
    Oncotarget; 2015 Feb; 6(6):3977-87. PubMed ID: 25738357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.
    Sato D; Kurihara Y; Kondo S; Shirota T; Urata Y; Fujiwara T; Shintani S
    Oncol Rep; 2013 Dec; 30(6):2659-64. PubMed ID: 24065118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
    Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
    Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].
    Fujiwara T; Tanaka N
    Nihon Rinsho; 2007 Oct; 65(10):1913-22. PubMed ID: 17926546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death.
    Alonso MM; Jiang H; Yokoyama T; Xu J; Bekele NB; Lang FF; Kondo S; Gomez-Manzano C; Fueyo J
    Mol Ther; 2008 Mar; 16(3):487-93. PubMed ID: 18253154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
    Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
    Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.
    Huang P; Watanabe M; Kaku H; Kashiwakura Y; Chen J; Saika T; Nasu Y; Fujiwara T; Urata Y; Kumon H
    Cancer Gene Ther; 2008 May; 15(5):315-22. PubMed ID: 18274558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma.
    Huang P; Kaku H; Chen J; Kashiwakura Y; Saika T; Nasu Y; Urata Y; Fujiwara T; Watanabe M; Kumon H
    Cancer Gene Ther; 2010 Jul; 17(7):484-91. PubMed ID: 20168351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
    Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death.
    Jiang H; Gomez-Manzano C; Aoki H; Alonso MM; Kondo S; McCormick F; Xu J; Kondo Y; Bekele BN; Colman H; Lang FF; Fueyo J
    J Natl Cancer Inst; 2007 Sep; 99(18):1410-4. PubMed ID: 17848677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.